Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 3 |
2022 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant.
J Dtsch Dermatol Ges. 2021 Jul;19 Suppl 1:37-39. doi: 10.1111/ddg.14480.
J Dtsch Dermatol Ges. 2021.
PMID: 33835653
No abstract available.
Adjuvant pembrolizumab-related hyperprogression in stage III melanoma.
Ammann NL, Geidel G, Schneider SW, Gebhardt C.
Ammann NL, et al.
J Dtsch Dermatol Ges. 2021 Sep;19(9):1341-1345. doi: 10.1111/ddg.14535. Epub 2021 Jul 13.
J Dtsch Dermatol Ges. 2021.
PMID: 34255418
No abstract available.
Item in Clipboard
Adjuvante Pembrolizumab-assoziierte Hyperprogression eines Melanoms im Stadium III.
Ammann NL, Geidel G, Schneider SW, Gebhardt C.
Ammann NL, et al.
J Dtsch Dermatol Ges. 2021 Sep;19(9):1341-1345. doi: 10.1111/ddg.14535_g.
J Dtsch Dermatol Ges. 2021.
PMID: 34541804
No abstract available.
Item in Clipboard
Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma.
Ammann NL, Schwietzer YF, Mess C, Stadler JC, Geidel G, Kött J, Pantel K, Schneider SW, Utikal J, Bauer AT, Gebhardt C.
Ammann NL, et al.
Cancers (Basel). 2022 Nov 18;14(22):5676. doi: 10.3390/cancers14225676.
Cancers (Basel). 2022.
PMID: 36428768
Free PMC article.
Item in Clipboard
Cite
Cite